JOHN K CHAN, MD
Medical Practice at Bascom Ave, San Jose, CA
License number
California A61661
Category
Medical Practice
Type
Obstetrics & Gynecology
License number
California A61661
Category
Medical Practice
Type
Gynecologic Oncology
Address
Address
2
751 S Bascom Ave DEPT GYN, San Jose, CA 95128
1006 Avalon Ave, San Mateo, CA 94404
1006 Avalon Ave, San Mateo, CA 94404
Phone
(408) 885-5000
(650) 283-0220
(650) 283-0220
Personal information
See more information about JOHN K CHAN at radaris.comName
Address
Phone
4405 Louisiana St, San Diego, CA 92116
430 Ravenswood Ave APT 1, Menlo Park, CA 94025
428 Arbolada Dr, Arcadia, CA 91006
4412 Pebble Creek Dr, Bakersfield, CA 93312
447 Monterey Blvd, San Francisco, CA 94127
Professional information
See more information about JOHN K CHAN at trustoria.com
John Chan - San Jose, CA
John Chan - San Jose, CA
Work:
Mix-Signal
Genesis Microchips / ST Microelectronic - senior mask designer (direct) Genesis Microchips
Mask design consultant GlobespanVirata
Senior mask designer LSI
Mask Design Consultant Spatial Light
Mask design consultant Intel
Mask design consultant Sony Electronic
Mask design consultant VLSI - Mask
design consultant Intel Corp
Mask design consultant Virage Logic
Mask design consultant Altera Corp
Senior Mask Tandem Computer
Engineer Consultant in SPICE simulation Vitesse Semiconductor
Design Engineer
Genesis Microchips / ST Microelectronic - senior mask designer (direct) Genesis Microchips
Mask design consultant GlobespanVirata
Senior mask designer LSI
Mask Design Consultant Spatial Light
Mask design consultant Intel
Mask design consultant Sony Electronic
Mask design consultant VLSI - Mask
design consultant Intel Corp
Mask design consultant Virage Logic
Mask design consultant Altera Corp
Senior Mask Tandem Computer
Engineer Consultant in SPICE simulation Vitesse Semiconductor
Design Engineer
Education:
University of California - Los Angeles, CA
BSEE
BSEE
John Chung-Kai Chan, San Jose CA
John Chung-Kai Chan, San Jose CA
Specialties:
Obstetrics & Gynecology, Gynecologic Oncology
Work:
Santa Clara Valley Medical Center
751 S Bascom Ave, San Jose, CA 95128 University of California at San Francisco
1600 Divisadero St, San Francisco, CA 94115 John C Chau
3905 Sacramento St, San Francisco, CA 94118
751 S Bascom Ave, San Jose, CA 95128 University of California at San Francisco
1600 Divisadero St, San Francisco, CA 94115 John C Chau
3905 Sacramento St, San Francisco, CA 94118
Education:
University of California at Los Angeles (1995), University of California Irvine Medical Center (1999) *, Anderson Cancer Center (1999) *Gynecologic Oncology, University of California Irvine Medical Center (1999) *Gynecologic Oncology
John K Chan, San Jose CA
John K Chan, San Jose CA
Specialties:
OB-GYN
Address:
751 S Bascom Ave, San Jose, CA 95128
Education:
National Taiwan University, College of Medicine - Doctor of Medicine
Los Angeles County-USC Medical Center - Residency - Pathology
Ronald Reagan UCLA Medical Center - Residency - Pathology
Los Angeles County-USC Medical Center - Residency - Pathology
Ronald Reagan UCLA Medical Center - Residency - Pathology
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Treatment Response To Anti-Angiogenic Therapies
Treatment Response To Anti-Angiogenic Therapies
US Patent:
2012022, Sep 6, 2012
Filed:
Mar 5, 2012
Appl. No.:
13/412610
Inventors:
John K. Chan - Foster City CA, US
International Classification:
A61K 39/395, C12Q 1/02, C40B 30/00, C12Q 1/68, A61P 35/00, A61P 9/00
US Classification:
4241331, 506 7, 435 61, 435 29
Abstract:
Methods are provided for selecting and treating patients with an anti-angiogenic agent and methods for reducing the risk of adverse events in patients from treatment with an anti-angiogenic agent, comprising the steps: obtaining a sample of tumor and normal tissues from a patient; determining the miRNA or protein expression in said samples; comparing the miRNA or protein expression in said tumor sample to the miRNA or protein expression in normal tissue; determining whether said tumor miRNA or protein expression is higher or lower than said normal miRNA or protein expression, wherein if said miRNA or protein expression indicates that the expression of at least one angiogenic gene is upregulated, the patient is scheduled for treatment with an anti-angiogenic agent. Preferably the anti-angiogenic agent is a VEGF-targeting agent or a tyrosine kinase inhibitor. In preferred embodiments, the VEGF-targeting agent is bevacizumab.